Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -92.38% | -3.04% | -27.13% | -39.87% | -61.75% |
Total Depreciation and Amortization | 71.47% | -5.01% | 61.79% | 97.88% | 135.00% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 96.49% | 57.55% | 20.09% | 43.04% | 123.43% |
Change in Net Operating Assets | 153.66% | 159.75% | -1.41% | -49.36% | -1,775.21% |
Cash from Operations | -55.82% | 18.78% | -21.87% | -39.53% | -65.54% |
Capital Expenditure | 37.20% | -512.35% | 70.21% | -28.56% | 74.09% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | 390,387.32% | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 0.00% | -100.00% | -- | -- | -- |
Cash from Investing | 11,171.38% | -1,214.70% | -103.70% | -24.59% | 68.82% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -202.74% | -9,429.17% | -8.33% | -8.33% | -2,917.39% |
Issuance of Common Stock | -84.34% | -65.14% | 6,804.96% | 615.47% | -44.76% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -86.81% | -69.38% | 6,848.03% | 623.05% | -45.23% |
Foreign Exchange rate Adjustments | -2,900.00% | 450.43% | -165.19% | -10,850.00% | 140.39% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 3,863.80% | -139.19% | 369.41% | -24.16% | -95.52% |